KYMR - NASDAQ
Kymera Therapeutics, Inc.
$73.25
+0.77%Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
At a Glance
Live Snapshotkymr
Total Debt
Last Annual Value
82.25M
3-Year CAGR
68%
5-Year CAGR
36%
10-Year CAGR
61%
Kymera Therapeutics, Inc. Competitors Analysis of Total Debt
| Company | Total Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Kymera Therapeutics, Inc. NASDAQ:KYMR | 82.25M | -1.0% | 35.6% | N/A | |
 Immunovant, Inc. NASDAQ:IMVT | 72.00K | -61.1% | -53.8% | N/A | |
 Viking Therapeutics, Inc. NASDAQ:VKTX | 137.00K | -52.3% | 36.4% | -27.2% | |
 Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX | 48.54M | -2.1% | 73.7% | 72.2% | |
 NewAmsterdam Pharma Company N.V. NASDAQ:NAMS | 202.00K | 49.9% | 1.6% | N/A | |
 ACADIA Pharmaceuticals Inc. NASDAQ:ACAD | 52.19M | -3.0% | -4.1% | N/A | |
 Arcellx, Inc. NASDAQ:ACLX | 96.26M | -0.5% | N/A | N/A | |
 Soleno Therapeutics, Inc. NASDAQ:SLNO | 2.69M | 88.3% | 42.5% | N/A | |
 Akero Therapeutics, Inc. NASDAQ:AKRO | 36.46M | 11.5% | 88.9% | N/A | |
 Praxis Precision Medicines, Inc. NASDAQ:PRAX | 110.00K | -64.7% | -52.0% | N/A |
Kymera Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your KYMR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.